Patent Grant
7511062
The present invention relates to substituted 2-quinolyl-oxazoles, thiazoles, imidazoles and pyrazoles, pharmaceutical compositions comprising them, and their use as PDE4 inhibitors for treating a variety of diseases such as allergic and inflammatory diseases, CNS diseases and diabetes. Combinations with other agents useful in the treatment of several diseases are also claimed.
Phosphodiesterases are known to regulate cyclic AMP, and phosphodiesterase 4 (PDE4) has been shown to be the predominant regulator of cyclic AMP in respiratory smooth muscle and inflammatory cells. Inhibitors of PDE4 are useful in treating a variety of diseases, including allergic and inflammatory diseases, diabetes, central nervous system diseases, pain, and viruses that produce TNF.
Amino-substituted quinolyl PDE4 inhibitors are disclosed in U.S. Pat. No. 5,804,588; sulfonamide-substituted quinolyl PDE4 inhibitors are disclosed in U.S. Pat. No. 5,834,485; and (benzo-fused)heteroaryl-substituted PDE4 inhibitors are disclosed in U.S. Pat. No. 6,069,151.
The present invention relates to a compound having the structural formula I
or a pharmaceutically acceptable salt or solvate thereof, wherein
R is H or alkyl;
X is O or S;
R1 is H, alkyl, cycloalkyl, cycloalkyl(C1-C4)alkyl-, —CH2F, —CHF2, —CF3, —C(O)alkyl or —C(O)NR18R19;
R3 and R4 are independently selected from the group consisting of H, alkyl, hydroxyalkyl and —C(O)Oalkyl;
R5 and R6 are independently selected from the group consisting of H, alkyl, hydroxyalkyl, alkoxyalkyl, mercaptoalkyl, —CH2F, —CHF2, —CF3, —C(O)OH, —C(O)Oalkyl and —C(O)NR43R44;
t is 1 or 2;
R7 is H, alkyl, alkenyl, hydroxyalkyl, cycloalkyl, alkoxyalkyl, aminoalkyl, (R17-phenyl)alkyl or —CH2—C(O)—O-alkyl;
R8 is H, alkyl, alkenyl, alkoxy, alkoxyalkyl, hydroxyalkyl, dihydroxyalkyl, alkyl-NR18R19, cyanoalkyl, haloalkyl, R23-heteroaryl, R23-heteroarylalkyl, R36-heterocycloalkyl, (R36-heterocycloalkyl)alkyl, R17-phenyl, (R17-phenyl)alkyl, R17-naphthyl, (R17-naphthyl)alkyl, R17-benzyloxy, -alkyl-C(O)—NR18R19, -alkyl-C(O)—N(R30)—(R23-heteroaryl), -alkyl-C(O)—(R17-phenyl), -alkyl-C(O)—(R36-heterocycloalkyl); -alkyl-N(R30)—C(O)Oalkyl, -alkyl-N(R30)—C(O)—NR18R19, -alkyl-N(R30)—C(O)alkyl, -alkyl-N(R30)—C(O)-(fluoroalkyl), -alkyl-N(R30)—C(O)—(R39-cycloalkyl), -alkyl-N(R30)—C(O)—(R17-phenyl), -alkyl-N(R30)—C(O)—(R23-heteroaryl), -alkyl-N(R30)—C(O)-alkylene-(R23-heteroaryl), -alkyl-NH—SO2—NR18R19, -alkyl-N(R30)—(R17-phenyl), -alkyl-N(R30)—(R23-heteroaryl), -alkyl-O—(R17-phenyl), -alkyl-O—(R23-heteroaryl), -alkyl-N(R30)—SO2-alkyl, alkylthioalkyl-, alkyl-SO2-alkyl-, (R35-phenylalkyl)-S-alkyl-, (hydroxyalkyl)-S-alkyl-, (alkoxyalkyl)-S-alkyl-, -alkyl-CO2-alkyl, R45-hydroxyalkyl, dihydroxyalkyl substituted by R17-benzyloxy, dihydroxyalkyl substituted by R17-phenyl, alkoxyalkyl substituted by R17-phenyl, (R17-phenyl)alkyl substituted by —CO2alkyl, (R17-phenyl)alkyl substituted by —C(O)N(R30)2, alkyl substituted by (R23-heteroaryl) and —C(O)NR37R38, haloalkyl substituted by CO2alkyl, R12-cycloalkyl, (R12-cycloalkyl)alkyl,
or R7 and R8 and the nitrogen to which they are attached together form a ring system selected from the group consisting of
comprises an R35-substituted 5 or 6-membered heteroaryl group fused to the piperidinyl or pyrrolidinyl ring;
p is 0 or 1;
q is 0 or 1;
the dotted line represents an optional double bond;
R9 is H, halo, alkyl, cycloalkyl, —CH2F, —CHF2 or CF3;
R10, R11, and R13 are independently selected from the group consisting of H and halo;
R12 is 1-3 substituents independently selected from the group consisting of H, alkyl, hydroxy, alkoxy, hydroxyalkyl, alkoxyalkyl, —C(O)Oalkyl, —(CH2)n—N(R30)—C(O)-cycloalkyl, —(CH2)n—N(R30)—C(O)alkyl, —(CH2)n—N(R30)—C(O)Oalkyl, —(CH2)n—N(R30)—(R23-heteroaryl), —(CH2)n—N(R30)—C(O)—NR18R19, —(CH2)n—C(O)—NR18R19, R17-phenyl, R35-heteroarylalkyl, R35-heteroaryloxy, —C(O)-heterocycloalkyl, —O—C(O)-heterocycloalkyl, —O—C(O)—NR18R19, —NH—SO2-alkyl, —NH—C(═NH)NH2, and
or two R12 substituents on the same carbon form ═O, ═NOR30 or ═CH2;
R14 is 1 or 2 substituents independently selected from the group consisting of H, OH, halo, alkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, —CF3, CN, R17-phenyl, (R17-phenyl)alkyl, —NR18R19, alkyl-NR18R19, —(CH2)n—C(O)OH, —(CH2)n—C(O)Oalkyl, —(CH2)n—C(O)alkyl, —(CH2)n—C(O)(R35-phenyl), —(CH2)n—C(O)(R23-heteroaryl), —(CH2)n—C(O)NR18R19, —(CH2)n—C(O)N(R30)—(CH2)n—(R23-heteroaryl), —(CH2)n—N(R30)—C(O)alkyl, —(CH2)n—N(R30)—C(O)-(fluoroalkyl), —(CH2)n—N(R30)—C(O)-(cycloalkyl), —(CH2)n—N(R30)—C(O)(R35-phenyl), —(CH2)n—N(R30)—C(O)(R23-heteroaryl), —(CH2)n—N(R30)C(O)NR18R19, —(CH2)n—N(R30)—C(O)Oalkyl, —(CH2)n—N(R30)cycloalkyl, —(CH2)n—N(R30)(R17-phenyl), —(CH2)n—N(R30)(R23-heteroaryl), —(CH2)n—N(R18)SO2alkyl, —(CH2)n—N(R20)SO2—(R17-phenyl), —(CH2)n—N(R30)SO2—CF3, —CH2S(O)0-2(R35-phenyl), —(CH2)n—OC(O)N(R30)alkyl, R23-heteroaryl, (R23-heteroaryl)alkyl, (R23-heteroaryl)oxy, (R23-heteroaryl)amino, —CH(OH)—(R17-phenyl), —CH(OH)—(R23-heteroaryl), —C(═NOR30)—(R17-phenyl), —C(═NOR30)—(R23-heteroaryl), morpholinyl, thiomorpholinyl,
w is 0 or 1;
or two R14 substituents and the carbon to which they are both attached form —C(═NOR30)— or —C(O)—;
each n is independently 0, 1, 2 or 3;
R15 is H, alkyl, cycloalkyl, (cycloalkyl)alkyl, hydroxyalkyl, alkoxyalkyl, haloalkyl, —C(O)Oalkyl, —C(O)O(R30-cycloalkyl), -alkyl-C(O)O-alkyl, —C(O)O-alkylene-(R35-phenyl), R17-phenyl, (R17-phenyl)alkyl, —CH—(R17-phenyl)2, R23-heteroaryl, —(CH2), —C(O)NR18R19, —SO2-alkyl, —SO2-cycloalkyl, —SO2—CF3, —SO2—(R35-phenyl), —SO2—NR18R19, —C(O)alkyl, —C(O)-(fluoroalkyl), —C(O)—C(CH3)(CF3)2, —C(O)—(R17-phenyl), —C(O)—(R23-heteroaryl), —C(O)-hydroxyalkyl, —C(O)-alkoxyalkyl, —C(O)—(R39-cycloalkyl), —C(O)-alkylene-(R17-phenyl), —C(O)-alkylene-(R23-heteroaryl), —C(O)-alkylene-S—C(O)alkyl, —C(═S)—(R17-phenyl), hydroxyalkyl substituted by R17-phenyl, hydroxyalkyl substituted by R23-heteroaryl, alkoxyalkyl substituted by R17-phenyl, alkoxyalkyl substituted by R23-heteroaryl,
wherein z is 0, 1 or 2;
R16 is 1 to 4 substituents independently selected from the group consisting of H, alkyl, R17-phenyl, (R17-phenyl)alkyl, (R23-heteroaryl)alkyl, hydroxyalkyl, alkoxyalkyl and —C(O)Oalkyl, or two R16 groups and the carbon to which they are both attached form —C(O)—;
R17 is 1 to 3 substituents independently selected from the group consisting of H, halo, alkyl, cycloalkyl, —OH, hydroxyalkyl, alkoxy, alkoxyalkyl, —CN, —CF3, —OCF3, —OCHF2, —OCH2F, —C(O)OH, —C(O)Oalkyl, —C(O)O—(R35-phenyl), —C(O)alkyl, —C(O)—(R35-phenyl), —SOalkyl, —SO2alkyl, —SO2—CF3, alkylthio, —NR43R44, -alkyl-NR43R44, R35-phenyl, R35-phenoxy, R35-heteroaryl, R35-heteroaryloxy, R36-heterocycloalkyl, —C(O)—(R36-heterocycloalkyl), hydroxyalkyl-NH—, —C(O)N(R30)2, —N(R43)—(R35-cycloalkyl) and —C(═NOR30); or two R17 substituents on adjacent carbon atoms together form —O—CH2—O—, —O—(CH2)2—O—, —(CH2)2—O— or —O—CH2—O—CH2—;
R18 and R19 are independently selected from the group consisting of H, alkyl, hydroxyalkyl, alkoxyalkyl, haloalkyl, R17-phenyl, (R17-phenyl)alkyl, naphthyl and cycloalkyl;
R20 is H, alkyl, or cycloalkyl;
R22 is 1 to 4 substituents independently selected from the group consisting of H, alkyl, hydroxy, alkoxy, halo, —CF3, —NH2 and R35-phenyl;
R23 is 1 to 4 substituents independently selected from the group consisting of H, alkyl, hydroxy, alkoxy, halo, —CF3, —NR18R19, —CN, —C(O)Oalkyl, —SO2-alkyl, —NHSO2-alkyl, R35-phenyl, R35-heteroaryl, morpholinyl, and —(CH2)n—C(O)—N(R30)2;
R24 is H, OH or alkoxy; or when the optional double bond is present, R24 and the adjacent carbon atom form the double bond;
R25 is H or R35-phenyl;
R27 is 1 to 3 substituents independently selected from the group consisting of H, halo, OH, alkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, haloalkyl, —CN, —C(O)OH, —C(O)Oalkyl, —C(O)N(R30)(R18), —C(O)—(R36-hetercycloalkyl), R17-phenyl, (R17-phenyl)-alkyl, R23-heteroaryl, (R23-heteroaryl)alkyl, (R23-heteroaryl)oxy, (R23-heteroaryl)amino NR18R19, NR18R19-alkyl, —(CH2)n—N(R30)—C(O)alkyl, —(CH2)n—N(R30)—C(O)-(fluoroalkyl), —(CH2)n—N(R30)—C(O)alkoxyalkyl, —(CH2)n—N(R30)—C(O)(cycloalkyl), —(CH2)n—N(R30)—(R23-heteroaryl), —(CH2)n—N(R30)—C(O)—(R23-heteroaryl), —(CH2)n—N(R30)—C(O)O-alkyl, —(CH2)n—N(R30)—C(O)O—(CF3-alkyl), —(CH2)n—N(R30)—C(O)O—(R39-cycloalkyl), —(CH2)n—N(R30)—C(O)O-alkylene-cycloalkyl, —(CH2)n—N(R30)—C(O)—N(R30)(R20), —(CH2)n—N(R30)—SO2-alkyl, —(CH2)—N(R30)—SO2—CF3, —(CH2)n—N(R30)—SO2—N(R30)2 and
or two R27 groups and the carbon to which they are both attached form —C(═NOR30)— or —C(O)—;
R28 is H, alkyl, R35-benzyl or -alkyl-C(O)O-alkyl;
R29 is alkyl, haloalkyl, —C(O)Oalkyl, —C(O)alkyl, —C(O)CF3, —C(O)—(R12-cycloalkyl), —C(O)—(R17-phenyl), —C(O)—(R23-heteroaryl), —C(O)—(R36-hetercycloalkyl), —SO2-alkyl, —SO2—(R35-phenyl), —C(O)NR18R19, R35-phenyl, (R35-phenyl)alkyl or R23-heteroaryl;
R30 is independently selected from the group consisting of H, alkyl, R35-benzyl and R35-phenyl;
R31 is H, alkyl, R35-benzyl or phenoxyalkyl;
R33 is H, OH or alkoxy;
R34 is H, alkyl, hydroxyalkyl, alkoxyalkyl or —C(O)Oalkyl;
R35 is 1 to 3 substituents independently selected from the group consisting of H, halo, alkyl, OH, —CF3, alkoxy, —CO2alkyl and —N(R43)(R44);
R36 is 1 or 2 substituents independently selected from the group consisting of H, alkyl, R17-phenyl, —OH, hydroxyalkyl, alkoxyalkyl, —C(O)Oalkyl and —NR18R19; or two R36 groups and the carbon to which they are both attached form —C(═NOR30)— or —C(O)—;
R37 and R38 are independently selected from the group consisting of H and alkyl, or R37 and R38 together are —(CH2)3— or —(CH2)4—, and together with the nitrogen to which they are attached, form a ring;
R39 is H, OH, alkyl, alkoxy, or CF3;
R40 is —OR30 or —NHC(O)alkyl;
R41 is H or —SO2alkyl;
R42 is —(CH2)n—(R35-phenyl), —(CH2)n—(R23-heteroaryl), —C(O)Oalkyl or —C(O)alkyl;
R43 and R44 are independently selected from the group consisting of H and alkyl; and
R45 is 1 or 2 substituents independently selected from the group consisting of halo, alkoxyalkyl, —CO2alkyl, R17-phenyl, R23-heteroaryl and cycloalkyl.
This invention also provides a method of treating diseases mediated by PDE 4, including allergic and inflammatory diseases, CNS diseases, and diabetes comprising administering an effective amount of at least one compound of formula I to a patient in need of such treatment.
In particular, this invention also provides a method of treating a PDE4 mediated disease or condition selected from the group consisting of: pain (e.g., acute pain, acute inflammatory pain, chronic inflammatory pain, and neuropathic pain), acute inflammation, chronic inflammation, rheumatoid arthritis, psoriasis, atopic dermatitis, asthma, COPD, adult respiratory disease, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, stroke, ischemia reperfusion injury, renal reperfusion injury, glomerulonephritis, Parkinson's disease, Alzheimer's disease, mild cognitive impairment (MCI), depression, anxiety, graft vs. host reaction (i.e., graft vs. host disease), allograft rejections (e.g., acute allograft rejection, and chronic allograft rejection), acute respiratory distress syndrome, delayed type hypersensitivity reaction, atherosclerosis, cerebral ischemia, osteoarthritis, multiple sclerosis, angiogenesis, osteoporosis, gingivitis, respiratory viruses, herpes viruses, hepatitis viruses, HIV, Kaposi's sarcoma associated virus (i.e., Kaposi's sarcoma), meningitis, cystic fibrosis, pre-term labor, cough, pruritis, multi-organ dysfunction, psoriatic arthritis, herpes, encephalitis, traumatic brain injury, CNS tumors, interstitial pneumonitis, hypersensitivity, crystal induced arthritis, acute pancreatitis, chronic pancreatitis, acute alcoholic hepatitis, necrotizing enterocolitis, chronic sinusitis, ocular inflammation, corneal neovascularization, polymyositis, acne, esophagitis, glossitis, airflow obstruction, airway hyperresponsiveness (i.e., airway hyperreactivity), bronchiectasis, bronchiolitis, bronchiolitis obliterans (i.e., bronchiolitis obliterans syndrome), chronic bronchitis, dyspnea, emphysema, hypercapnea, hyperinflation, hypoxemia, hyperoxia-induced inflammations, hypoxia, pulmonary fibrosis, pulmonary hypertension, peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD), granulocytic ehrlichiosis, sarcoidosis, small airway disease, ventilation-perfusion mismatching, wheeze, colds, gout, alcoholic liver disease, lupus, periodontitis, cancer, transplant reperfusion injury, early transplantation rejection (e.g., acute allograft rejection), airway hyperreactivity, allergic contact dermatitis, allergic rhinitis, alopecia areata, autoimmune deafness (including, for example, Meniere's disease), autoimmune hemolytic syndromes, autoimmune hepatitis, autoimmune neuropathy, autoimmune ovarian failure, autoimmune orchitis, autoimmune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, cirrhosis, dermatomyositis, diabetes, drug-induced autoimmunity, endometriosis, fibrotic diseases, gastritis, Goodpasture's syndrome, Graves' disease, Gullain-Barre disease, Hashimoto's thyroiditis, hepatitis-associated autoimmunity, HIV-related autoimmune syndromes and hematologic disorders, hypophytis, interstitial cystitis, juvenile arthritis, Langerhans' cell histiocytitis, lichen planus, metal-induced autoimmunity, myocarditis (including viral myocarditis), myositis, neuropathies (including, for example, IgA neuropathy, membranous neuropathy and idiopathic neuropathy), nephritic syndrome, optic neuritis, pancreatitis, post-infectious autoimmunity, primary biliary cirrhosis, reactive arthritis, ankylosing spondylitis, Reiter's syndrome, reperfusion injury, scleritis, scleroderma, secondary hematologic manifestation of autoimmune diseases (such as anemias), silicone implant associated autoimmune disease, Sjogren's syndrome, systemic lupus erythematosus, transverse myelitis, tubulointerstitial nephritis, uveitis, and vitiglio in a patient in need of such treatment comprising administering to said patient an effective amount of at least one compound of formula I, or a pharmaceutically acceptable salt or solvate thereof.
Compounds of formula I are preferably useful in treating pain (e.g., acute pain, acute inflammatory pain, chronic inflammatory pain, and neuropathic pain), acute inflammation, chronic inflammation, rheumatoid arthritis, psoriasis, atopic dermatitis, asthma, COPD, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, stroke, ischemia reperfusion injury, glomerulonephritis, Parkinson's disease, Alzheimer's disease, mild cognitive impairment, depression, anxiety, graft vs. host reaction (i.e., graft vs. host disease), allograft rejections (e.g., acute allograft rejection, and chronic allograft rejection), delayed type hypersensitivity reaction, osteoarthritis, multiple sclerosis, angiogenesis, osteoporosis, HIV, cough, psoriatic arthritis, CNS tumors, necrotizing enterocolitis, airflow obstruction, airway hyperresponsiveness (i.e., airway hyperreactivity), bronchiolitis, chronic bronchitis, emphysema, pulmonary fibrosis, pulmonary hypertension, small airway disease, wheeze, lupus, cancer, transplant reperfusion injury, early transplantation rejection (e.g., acute allograft rejection), airway hyperreactivity, allergic contact dermatitis, allergic rhinitis, diabetes, juvenile arthritis, reactive arthritis, ankylosing spondylitis, reperfusion injury, and systemic lupus erythematosus.
More preferably, compounds of formula I are useful for treating COPD, asthma, IBD, dermatitis, MS, arthritis, Parkinson's disease, Alzheimer's disease, mild cognitive impairment, depression and anxiety.
Preferred veterinary uses for compounds of formula I include the treatment of dermatitis in dogs and the treatment of recurrent airway disease in horses.
This invention also provides a method of treating a PDE4 mediated disease or condition in a patient in need of such treatment comprising administering to said patient at least one compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one other medicament (e.g., a drug, agent or therapeutic) selected from the group consisting of:
This invention also provides a method of treating a pulmonary disease (e.g., COPD, asthma or cystic fibrosis) in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of: glucocorticoids, 5-lipoxygenase inhibitors, β-2 adrenoceptor agonists, muscarinic M1 antagonists, muscarinic M3 antagonists, muscarinic M2 agonists, NK3 antagonists, LTB4 antagonists, cysteinyl leukotriene antagonists, bronchodilators, PDE4 inhibitors, PDE inhibitors, elastase inhibitors, MMP inhibitors, phospholipase A2 inhibitors, phospholipase D inhibitors, histamine H1 antagonists, histamine H3 antagonists, dopamine agonists, adenosine A2 agonists, NK1 and NK2 antagonists, GABA-b agonists, nociceptin agonists, expectorants, mucolytic agents, decongestants, antioxidants, anti-IL-8 anti-bodies, anti-IL-5 antibodies, anti-IgE antibodies, anti-TNF antibodies, IL-10, adhesion molecule inhibitors, and growth hormones.
This invention also provides a method of treating multiple sclerosis in a patient in need of such treatment comprising administering to said patient, a therapeutically effective amount of at least one compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of glatiramer acetate, glucocorticoids, methotrexate, azothioprine, mitoxantrone, chemokine inhibitors, and CB2-selective agents.
This invention also provides a method of treating multiple sclerosis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of: methotrexate, cyclosporin, leflunimide, sulfasalazine, β-methasone, β-interferon, glatiramer acetate, and prednisone.
This invention also provides a method of treating rheumatoid arthritis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of COX-2 inhibitors, COX inhibitors, immunosuppressives (e.g., methotrexate, cyclosporin, leflunimide and sulfasalazine), steroids (e.g., betamethasone, cortisone and dexamethasone), anti-TNF-α compounds, MMP inhibitors, glucocorticoids, chemokine inhibitors, CB2-selective inhibitors, and other classes of compounds indicated for the treatment of rheumatoid arthritis.
This invention also provides a method of treating stroke and ischemia reperfusion injury in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of thrombolitics (e.g., tenecteplase, TPA, alteplase), antiplatelet agents (e.g., gpIIb/IIIa), antagonists (e.g., abciximab and eftiifbatide), anticoagulants (e.g., heparin), and other compounds indicated for the treatment of rheumatoid arthritis.
This invention also provides a method of treating stroke and ischemia reperfusion injury in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of tenecteplase, TPA, alteplase, abciximab, eftiifbatide, and heparin.
This invention also provides a method of treating psoriasis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of immunosuppressives (e.g., methotrexate, cyclosporin, leflunimide and sulfasalazine), steroids (e.g., β-methasone) and anti-TNF-α compounds (e.g., etonercept and infliximab).
This invention also provides a method of treating COPD in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of formula I, or a pharmaceutically acceptable salt or solvate thereof.
This invention also provides a method of treating arthritis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of formula I, or a pharmaceutically acceptable salt or solvate thereof.
This invention also provides a method of treating osteoarthritis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of formula I, or a pharmaceutically acceptable salt or solvate thereof.
This invention also provides a method of treating acute pain, acute inflammatory pain, chronic inflammatory pain, or neuropathic pain in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of formula I, or a pharmaceutically acceptable salt or solvate thereof.
This invention also provides a method of treating pain in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, and administering a therapeutically effective amount of at least one medicament selected from the group consisting of: NSAIDs, COXIB inhibitors, anti-depressants, and anti-convulsants.
This invention also provides a pharmaceutical composition comprising at least one (e.g., 1-3, usually 1) compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier. Preferred are oral dosage forms and dosage forms suitable for inhalation.
This invention also provides a pharmaceutical composition comprising at least one (e.g., 1-3, usually 1) compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, and at least one (e.g., 1-3, usually 1) other agent, medicament, antibody and/or inhibitor disclosed above, and a pharmaceutically acceptable carrier.
Preferred compounds of formula I are those wherein the quinolyl portion has the structure
More preferred are compounds wherein R10, R11 and R13 are each H. Also preferred are compounds wherein R1 is H, alkyl, cycloalkyl or CF3; more preferably, R1 is alkyl, especially methyl. Also preferred are compounds wherein R9 is H, alkyl or —CF3, more preferably —CF3.
In compounds of formula I, X is preferably O.
In compounds of formula I,
is preferably oxazolyl, more preferably
In compounds of formula I, R3 is preferably H, alkyl, hydroxalkyl or —C(O)Oalkyl, and R4 is H or alkyl. More preferably, R3 and R4 are each independently H or alkyl.
In compounds of formula I, R5 is preferably H, and R6 is preferably H, alkyl or hydroxyalkyl. When R6 is alkyl, it is preferably methyl, ethyl or isopropyl, more preferably methyl; when it is hydroxyalkyl, it is preferably hydroxymethyl or hydroxyethyl (i.e., —(CH2)2OH or —CH(OH)CH3). In a more preferred embodiment, R5 is H and R6 is H, methyl or hydroxymethyl. Preferably, t is 1. When t is 2, preferably both R5 substituents and one R6 substituent are H and one R6 substituent is H or methyl.
Preferably, R5 and R6 have the following stereochemistry (i.e., R6 is “S”):
When R7 and R8 do not form a ring, the following definitions are preferred.
R7 is preferably H, alkyl, cycloalkyl, hydroxyalkyl or alkoxyalkyl. More preferably, R7 is H, alkyl, hydroxyalkyl, especially wherein alkyl is methyl or ethyl, and hydroxyalkyl is hydroxyethyl. Especially preferred are compounds wherein R7 is H or alkyl, especially H, methyl or ethyl, with H being most preferred.
R8 is preferably R12-cycloalkyl, (R12-cycloalkyl)alkyl, R45-hydroxyalkyl, R17-phenyl, (R17-phenyl)alkyl, R23-heteroaryl, (R23-heteroaryl)alkyl, -alkyl-N(R30)—C(O)—NR18R19, -alkyl-N(R30)—C(O)alkyl, -alkyl-N(R30)—C(O)—(R17-phenyl), -alkyl-N(R30)—C(O)—(R23-heteroaryl), -alkyl-N(R30)—(R23-heteroaryl),
More preferably, R8 is R12-cycloalkyl, R45-hydroxyalkyl, (R17-phenyl)alkyl, R23-heteroaryl, (R23-heteroaryl)alkyl, -alkyl-N(R30)—(R23-heteroaryl), -alkyl-N(R30)—C(O)alkyl,
(especially where p is 0) or
(especially where p is 1). Especially preferred are compounds wherein R8 is R12-cycloalkyl, R45-hydroxyalkyl, (R17-phenyl)alkyl, (R23-heteroaryl)alkyl, -alkyl-N(R30)—C(O)-alkyl, -alkyl-N(R30)—(R23-heteroaryl) or
When R8 comprises R12-cycloalkyl, R12 is preferably OH, —(CH2)n—N(R30)—C(O)-cycloalkyl or —(CH2)n—N(R30)—(R23-heteroaryl), especially OH. When R8 is
n is preferably 0 and R29 is preferably heteroaryl, —C(O)alkyl or —C(O)cycloalkyl. When R8 is R45-hydroxyalkyl, R45 is preferably R17-phenyl.
R30 is preferably H.
Preferred heteroaryl groups include pyrimidyl, benzothienyl, benzofuranyl, indolyl, pyridyl and pyrazinyl.
Especially preferred are compounds of formula I wherein R7 is H and R8 is (R17-phenyl)alkyl, (R23-heteroaryl)alkyl, R45-hydroxyalkyl, -alkyl-N(R30)—(R23-heteroaryl) or
R17 is preferably 1-3 substituents selected from the group consisting of halogen, OH, alkoxy and alkyl; R23 is preferably 1 or 2 substituents independently selected from the group consisting of H, alkyl, alkoxy and halogen; R45 is preferably R17-phenyl, wherein R17 is 1-3 substituents selected from the group consisting of halogen, OH, alkoxy and alkyl; heteroaryl is pyrimidyl, benzothienyl, benzofuranyl, indolyl, pyridyl or pyrazinyl, and R30 is H.
Also preferred are compounds of formula I wherein R7 and R8 and the nitrogen to which they are attached form
In the preferred compounds where R7 and R8 form
the optional double bond preferably is not present (i.e., a single bond is present). R14 is preferably selected from H, OH, alkoxy, —(CH2)n—N(R30)(R23-heteroaryl), R23-heteroaryl or (R23-heteroaryl)-alkyl. In a further preferred embodiment, one R14 is OH and the other R14 is R23-heteroaryl; in another embodiment, one R14 is H and the other is (R23-heteroaryl)-alkyl or —(CH2)n—N(R30)(R23-heteroaryl) (especially wherein n is 1).
In the preferred compounds where R7 and R8 form
q is preferably 1. R27 is preferably 1-3 substituents independently selected from the group consisting of H, OH, alkyl, alkoxy, alkoxyalkyl, R17-phenyl, —C(O)OH, —C(O)Oalkyl, R23-heteroaryl, (R23-heteroaryl)amino and —(CH2)n—N(R30)—C(O)(cycloalkyl), wherein n is 0.
In the preferred compounds where R7 and R8 form
R15 is preferably alkyl, R17-phenyl, R23-heteroaryl, —C(O)alkyl, —C(O)(fluoroalkyl), —C(O)—(R23-heteroaryl), —C(O)-alkoxyalkyl, —C(O)—(R38-cycloalkyl), —SO2-alkyl, —SO2—NR18R19 or
R16 is preferably H, alkyl, or two R16 groups and the carbon to which they are attached form —C(O)—.
In the preferred compounds where R7 and R8 form
preferably p is 0, R34 is hydrogen, and R35 is 1 or 2 substituents independently selected from H, OH, halo and alkyl.
In the preferred compounds where R7 and R8 form
preferably p is 0, ring B is a pyrazolyl or thiazolyl ring, and R35 is 1 or 2 substituents independently selected from H and alkyl.
As used above, and throughout the specification, the following terms, unless otherwise indicated, shall be understood to have the following meanings:
“Patient” includes both humans and animals.
“Mammal” means humans and other mammalian animals.
“Alkyl” means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain. Non-limiting examples of suitable alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl and n-pentyl.
“Alkenyl” means an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched and comprising about 2 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkenyl chain. Non-limiting examples of suitable alkenyl groups include ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl and n-pentenyl.
“Alkylene” means a difunctional group obtained by removal of a hydrogen atom from an alkyl group that is defined above. Non-limiting examples of alkylene include methylene (i.e., —CH2—), ethylene (i.e., —CH2—CH2—) and branched chains such as —CH(CH3)—CH2—.
“Heteroaryl” means a single ring, bicyclic or benzofused heteroaromatic group of 5 to 10 atoms comprised of 2 to 9 carbon atoms and 1 to 4 heteroatoms independently selected from the group consisting of N, O and S, provided that the rings do not include adjacent oxygen and/or sulfur atoms. N-oxides of the ring nitrogens are also included. Examples of single-ring heteroaryl groups are pyridyl, oxazolyl, isoxazolyl, oxadiazolyl, furanyl, pyrrolyl, thienyl, imidazolyl, pyrazolyl, tetrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrazinyl, pyrimidyl, pyridazinyl and triazolyl. Examples of bicyclic heteroaryl groups are naphthyridyl (e.g., 1,5 or 1,7), imidazopyridyl, pyridopyrimidinyl and 7-azaindolyl. Examples of benzofused heteroaryl groups are indolyl, quinolyl, isoquinolyl, phthalazinyl, benzothienyl (i.e., thianaphthenyl), benzimidazolyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl and benzofurazanyl. All positional isomers are contemplated, e.g., 2-pyridyl, 3-pyridyl and 4-pyridyl. The term R23-heteroaryl refers to such groups wherein substitutable ring carbon atoms have a substituent as defined above. When the heteroaryl group is a benzofused ring, the substituents can be attached to either or both the phenyl ring portion and the heteroaromatic ring portion, and the heteroaryl group can be attached to the rest of the molecule either through the phenyl ring portion or the heteroaromatic ring portion.
“Cycloalkyl” means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 3 to about 6 carbon atoms. Non-limiting examples of suitable monocyclic cycloalkyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Non-limiting examples of suitable multicyclic cycloalkyls include 1-decalin, norbornyl, adamantyl and the like. Monocyclic rings are preferred.
“Halo” means fluoro, chloro, bromo, or iodo groups. Preferred are fluoro, chloro or bromo, and more preferred are fluoro and chloro.
“Haloalkyl” means an alkyl as defined above wherein one or more hydrogen atoms on the alkyl is replaced by a halo group defined above; in particular, fluoroalkyl refers to an alkyl chain substituted by one or more fluoro atoms.
“Aminoalkyl” means an alkyl as defined above wherein a hydrogen atom on the alkyl is replaced by an amino (i.e., —NH2) group.
“Heterocycloalkyl” means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more, preferably 1, 2, 3 or 4, of the atoms in the ring system is independently selected from an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocycloalkyls contain 5 to 6 ring atoms. The prefix aza, oxa or thia before the heterocycloalkyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. The nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S-dioxide. Non-limiting examples of suitable monocyclic heterocyclyl rings include piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,3-dioxolanyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like. The heterocycloalkyl group can be attached to the parent moiety through a ring carbon or a ring nitrogen.
“(Heterocycloalkyl)alkyl” means a heterocycloalkyl-alkyl group in which the heterocycloalkyl and alkyl groups are as defined above. The bond to the parent is through the alkyl.
“(Heteroaryl)alkyl” means a heteroaryl-alkyl- group in which the heteroaryl and alkyl are as previously described. Non-limiting examples of suitable heteroarylalkyl groups include pyridylmethyl, 2-(furan-3-yl)ethyl and quinolin-3-ylmethyl. The bond to the parent moiety is through the alkyl.
“(Phenyl)alkyl and “(naphthyl)alkyl similarly mean phenyl-alkyl and naphthyl-alkyl groups wherein the bond to the parent moiety is through the alkyl.
“Hydroxyalkyl” means a HO-alkyl- group in which alkyl is as previously defined. Non-limiting examples of suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl. Similarly, “dihydroxyalkyl” refers to a straight or branched alkyl chain substituted by two hydroxy groups.
“Alkoxy” means an alkyl-O— group in which the alkyl group is as previously described. Non-limiting examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy. The bond to the parent moiety is through the ether oxygen.
“Alkylthio” means an alkyl-S— group in which the alkyl group is as previously described. Non-limiting examples of suitable alkylthio groups include methylthio, ethylthio and isopropylthio. The bond to the parent moiety is through the sulfur.
“Heteroarylamino” means an heteroaryl-NH— group in which the heteroaryl group is as previously described. Non-limiting examples of suitable heteroarylamino groups include pyrimidinyl-amino and pyrazinyl-amino. The bond to the parent moiety is through the amino nitrogen.
“Heteroaryloxy” means an heteroaryl-O— group in which the heteroaryl group is as previously described. Non-limiting examples of suitable heteroaryloxy groups include pyrimidinyl-O— and pyrazinyl-O—. The bond to the parent moiety is through the ether oxygen.
The term “hydroxyalkyl substituted by CO2alkyl” means an alkyl chain substituted by a hydroxy group and a CO2alkyl group. Similarly, terms such as “hydroxyalkyl substituted by R17-phenyl” means an alkyl chain substituted by a hydroxy group and a R17-phenyl group; “hydroxyalkyl substituted by R17-phenyl and alkoxy” means an alkyl group substituted by a hydroxy group, a R17-phenyl, and an alkoxy group. In each of these substituents and other similar substituents listed in the definitions, the alkyl chains can be branched.
Examples of moieties formed when two adjacent R17 groups form a ring with the carbons on the phenyl ring to which they are attached are:
When R7 and R8 together form
the dotted line indicates an optional double bond as defined above. When the double bond is absent, i.e., when a single bond is present, the one or two R14 substituents can be attached to the same or different ring carbons. When the double bond is present, only one R14 substituent can be attached to a carbon that is part of the double bond.
When R7 and R8 together form
the dotted line indicates an optional double bond as defined above. When the double bond is absent, i.e., when a single bond is present, R24 can be H, OH or alkoxy and R25 can be H or R35-phenyl, but when the double bond is present, R24 forms the double bond with the adjacent carbon and R25 is H or R35-phenyl. That is, the moiety has the structural formula
When R7 and R8 together form
it means that an optionally substituted fused bicyclic ring is formed, wherein the
portion comprises an R35-substituted 5 or 6-membered heteroaryl group fused to the piperidinyl ring.
Examples are:
The term “optionally substituted” means optional substitution with the specified groups, radicals or moieties, in available position or positions.
With reference to the number of moieties (e.g., substituents, groups or rings) in a compound, unless otherwise defined, the phrases “one or more” and “at least one” mean that there can be as many moieties as chemically permitted, and the determination of the maximum number of such moieties is well within the knowledge of those skilled in the art.
As used herein, the term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
The wavy line as a bond generally indicates a mixture of, or either of, the possible isomers, e.g., containing (R)- and (S)-stereochemistry. For example,
Lines drawn into the ring systems, such as, for example:
indicate that the indicated line (bond) may be attached to any of the substitutable ring carbon atoms.
As well known in the art, a bond drawn from a particular atom wherein no moiety is depicted at the terminal end of the bond indicates a methyl group bound through that bond to the atom, unless stated otherwise. For example:
It should also be noted that any carbon or heteroatom with unsatisfied valences in the text, schemes, examples, structural formulae, and any Tables herein is assumed to have the hydrogen atom or atoms to satisfy the valences.
Prodrugs and solvates of the compounds of the invention are also contemplated herein. The term “prodrug”, as employed herein, denotes a compound that is a drug precursor which, upon administration to a subject, undergoes chemical conversion by metabolic or chemical processes to yield a compound of formula I or a salt and/or solvate thereof. A discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) Volume 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press, both of which are incorporated herein by reference thereto.
“Solvate” means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. “Solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. “Hydrate” is a solvate wherein the solvent molecule is H2O.
“Effective amount” or “therapeutically effective amount” is meant to describe an amount of compound or a composition of the present invention effective in inhibiting PDE4 and thus producing the desired therapeutic effect in a suitable patient.
The compounds of formula I form salts which are also within the scope of this invention. Reference to a compound of formula I herein is understood to include reference to salts thereof, unless otherwise indicated. The term “salt(s)”, as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a compound of formula I contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions (“inner salts”) may be formed and are included within the term “salt(s)” as used herein. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful. Salts of the compounds of the formula I may be formed, for example, by reacting a compound of formula I with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization. Acids (and bases) which are generally considered suitable for the formation of pharmaceutically useful salts from basic (or acidic) pharmaceutical compounds are discussed, for example, by S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33 201-217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; in The Orange Book (Food & Drug Administration, Washington, D.C. on their website); and P. Heinrich Stahl, Camille G. Wermuth (Eds.), Handbook of Pharmaceutical Salts: Properties, Selection, and Use, (2002) Int'l. Union of Pure and Applied Chemistry, pp. 330-331. These disclosures are incorporated herein by reference thereto.
Exemplary acid addition salts include acetates, adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides, hydrobromides, hydroiodides, 2-hydroxyethanesulfonates, lactates, maleates, methanesulfonates, methyl sulfates, 2-naphthalenesulfonates, nicotinates, nitrates, oxalates, pamoates, pectinates, persulfates, 3-phenylpropionates, phosphates, picrates, pivalates, propionates, salicylates, succinates, sulfates, sulfonates (such as those mentioned herein), tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) undecanoates, and the like.
Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, aluminum salts, zinc salts, salts with organic bases (for example, organic amines) such as benzathines, diethylamine, dicyclohexylamines, hydrabamines (formed with N,N-bis(dehydroabietyl)ethylenediamine), N-methyl-D-glucamines, N-methyl-D-glucamides, t-butyl amines, piperazine, phenylcyclohexylamine, choline, tromethamine, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g. methyl, ethyl, propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g. dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g. decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and others.
All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.
Compounds of formula I, and salts, solvates and prodrugs thereof, may exist in their tautomeric form (for example, as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present invention.
All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates and prodrugs of the compounds as well as the salts and solvates of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention. Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations. The use of the terms “salt”, “solvate” “prodrug” and the like, is intended to equally apply to the salt, solvate and prodrug of enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrugs of the inventive compounds.
Polymorphic forms of the compounds of Formula I, and of the salts, solvates and prodrugs of the compounds of Formula I, are intended to be included in the present invention.
This invention also includes the compounds of this invention in isolated and pure form.
Compounds of formula I can be prepared by known methods from starting materials either known in the art or prepared by methods known in the art. Non-limiting examples of suitable methods are illustrated in the following schemes.
In the schemes, the quinolyl portion is shown as the preferred structure, but those skilled in the art will recognize that other substitutions on the quinolyl portion can be made by these procedures. Also, one skilled in the art will recognize that the schemes show the significant steps of the procedures, and that the synthesis of compounds of formula I may require the need for the protection of certain functional groups during the preparation of the compounds; the synthesis of compounds also may require the reduction of a reducible functional group or the oxidation of an oxidizable functional group.
Step a
Formation of the oxazole ring can be accomplished by a number of methods including, but not limited to the following.
Using the appropriate starting materials, both the amine and ester functional groups can be incorporated when the oxazole ring is synthesized.
Step b
Introduction of the ester moiety COOR2 can be accomplished stepwise by reaction with phosphorous oxychloride and subsequent oxidation of the intermediate aldehyde to the carboxylic acid and further esterification. Alternatively, reaction at this position can proceed with a Lewis acid such as zinc triflate and an acid chloride.
Step c
Introduction of the R moiety can be accomplished by deprotonation with a strong base such as n-butyl lithium, sec-butyl lithium, lithium diisopropylamine or lithium hexamethyldisilazide, followed by addition of an aldehyde or alkyl halide. This reaction can use a variety of solvents including diethyl ether, THF, dioxane, hexane, toluene, HMPA, DMPU and TMEDA.
Step d
Activation of the R moiety in (3) can be accomplished by several different methods. If R is an alkyl moiety, halogenation, for example with bromine or N-bromo-succinimide and an initiator such as benzoyl peroxide, AIBN or light in carbon tetrachloride as the solvent provides (5) as a halide. If R incorporates an ester or alcohol functional group, through appropriate oxidation or reduction reactions, the aldehyde or ketone functional group can be obtained for further reaction in Step e through a reductive amination reaction. If R incorporates an ester, ketone, or aldehyde functional group, appropriate reduction reaction with a hydride such as NaBH4, LiBH4, LiAlH4, or diisobutylaluminum hydride will provide the alcohol moiety. This alcohol can be activated by conversion, for example, to the corresponding mesylate, tosylate, chloride, bromide or iodide.
Step e
Introduction of the amine moiety in (6) can be accomplished by an alkylation reaction on (5) if X is a leaving group such as chloride, bromide, mesylate or tosylate. This reaction can use a variety of bases including TEA, DIPEA, N-methyl morpholine, pyridine, dimethylaminopyridine, imidazole, K2CO3, Cs2CO3, potassium t-butoxide, and NaOH, and can be done in a variety of solvents including DMF, dimethylacetamide, THF, dioxane, CH3CN, toluene, CH2Cl2 and dichloroethane. Alternatively, if the —C(X)(R5)(R6) moiety incorporates a ketone or aldehyde functional group, the amine moiety can be introduced through a reductive amination reaction. Suitable reducing reagents for this reaction include NaBH3CN, sodium triacetoxyborohydride in a mixture of solvents including THF, dioxane, CH3CN, toluene, CH2Cl2, dichloroethane, methanol, ethanol, trifluoroethanol. The reductive amination reaction may require the addition of a drying agent such as sieves or MgSO4, or azeotropic removal of water or the addition of a Lewis acid such as titanium isopropoxide. In addition, the ketone or aldehyde moiety can be converted into an oxime with hydroxylamine and a variety of bases such as pyridine, TEA, sodium acetate, and Na2CO3. The oxime can be reduced to an amine.
Step f
Hydrolysis of ester (6) to acid (7) can be accomplished with a suitable base such as NaOH, LiOH, sodium methoxide, sodium ethoxide, K2CO3, Cs2CO3, BCl3, potassium t-butoxide, TEA, DBU and DIPEA in a mixture of solvents including water, methanol, ethanol, isopropanol, CH2Cl2, THF, diethyl ether and dioxane.
Step g
Amide bond formation to obtain (8) can be accomplished by formation of the acid chloride, a mixed anhydride, or activated ester and addition of the appropriate amine. A variety of suitable amide bond coupling reagents such as HATU, CDI, EDC, DCC, PyBOP, polymer supported CDI, polymer supported EDC and the like, with or without HOBt, can be used. These coupling reagents can be used with a suitable base such as TEA, DIPEA, N-methyl morpholine, pyridine, dimethylaminopyridine, DBU, imidazole and the like in a mixture of solvents including DMF, dimethylacetamide, THF, dioxane, CH3CN, N-methylpyrrolidine, CH2Cl2, and dichloroethane.
Abbreviations used in the above general schemes and in the following examples, as well as throughout the specification, are as follows: Me (methyl); Bu (butyl); Et (ethyl); Ac (acetyl); Boc or BOC (t-butoxycarbonyl); DMF (dimethyl-formamide); THF (tetrahydrofuran); DIPEA (diisopropylethylamine); RT (room temperature); HOBt (hydroxybenzotriazole); TFA (trifluoroacetic acid); TEA (triethyl amine); KHMDS (potassium bis(trimethylsilyl)amide); TLC (thin layer chromatography); EDC (1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride); HMPA (hexamethylphosphoramide); DMPU (1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone); TMEDA (N,N,N′,N′-tetramethyletheylenediamine); HATU (O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyl uranium hexafluoro-phosphate); NBS (N-bromosuccinimide); DCC (1,3-dicyclohexylcarbodiimide); DEC (1,2-diethylaminoethyl chloride hydrochloride); TMSCN (trimethylsilylcyanide); CDI (carbonyldiimidazole); PyBOP (benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate).
Step 1: SOCl2 (26.7 ml, 367 mmol) was added to a mixture of compound 1 (40 g, 147 mmol) in dry toluene (300 ml) and DMF (0.4 ml). The mixture was heated at 70° C. for 2 h, then the excess of SOCl2 and solvents were evaporated to dryness to obtain compound 2 as an off white-solid (41 g).
Step 2: A solution of compound 2 (41 g, 141 mmol) in CH2Cl2 (200 ml) was added slowly to a solution of L-threonine methyl ester HCl salt (29 g, 170 mmol) in CH2Cl2 (200 ml) and DIPEA (38 g, 296 mmol) at 0° C. The solution was stirred at 0° C., then warmed to RT over 3 h. After 3 h at RT, the mixture was washed with aqueous NH4Cl solution, then the solid was precipitated in the organic layer and filtered off to give compound 3 (54 g) as a white solid. MS: C17H17F3N2O5 [M+1]+387.1.
Step 3: SOCl2 (76.8 ml, 645 mmol) was added through a syringe to a suspension of compound 3 (50 g, 129 mmol) in dry CH2Cl2 (500 ml) cooled to −45 0° C. The mixture was stirred at −45° C. for 1 h, then warmed up to RT slowly. After the reaction was complete, solvent and excess SOCl2 were evaporated. The residue was dissolved in CH2Cl2 (800 ml) and washed with saturated NaHCO3 solution (3×600 ml), dried (Na2SO4), filtered and concentrated to give compound 4 as a beige solid (43 g, 120 mmol, 93%). MS: C17H15F3N2O4 [M+1]+369.1.
Step 4: DBU (13.9 ml, 93 mmol) was added via a syringe to a solution of compound 4 (31 g, 84 mmol) in dry CH2Cl2 (300 ml) at 0° C., followed by the addition of BrCCl3 (9.1 ml, 93 mmol). The mixture was stirred at 0° C. for 2 h, then at RT overnight. The reaction was quenched with 0.15 N HCl (400 ml) and extracted with CH2Cl2 (2×100 ml). The organic layer was dried with Na2SO4, filtered and concentrated to give crude title compound 5 (35 g). The crude material was triturated with MeOH (200 ml) and 23.5 g of compound 5 was collected as a pale yellow solid. MS: C17H13F3N2O4 [M+1]+367.1.
Step 1: NBS (23.5 g, 132 mmol) and benzoyl peroxide (1.4 g, 5.75 mmol) were added to a mixture of compound 5 (42 g, 115 mmol) in dry CCl4 (550 ml). The mixture was refluxed for 3 h, then concentrated by evaporating off most of the solvent. Saturated NH4Cl solution was added and the product was extracted from the aqueous layer with CH2Cl2 (2×300 ml). The organic fractions were combined, dried (Na2SO4), filtered and evaporated. The crude material was triturated with MeOH to give compound 6 as a white solid (49.5 g, 110 mmol, 96%). MS: C17H12F3BrN2O4 [M+1]+Br79,81 445.1, 447.1.
Step 2: Potassium phthalimide (20.6 g, 111 mmol) was added to a solution of compound 6 (49.5 g, 111 mmol) in dry DMF (650 ml) at RT. After stirring at RT for 2 h, the reaction mixture was poured into an ice water bath (1.5 L). The resultant yellow precipitate was collected, washed with water, and dried at 45° C. under vacuum to give compound 7 as a yellow solid (56 g, 110 mmol). MS: C25H16F3N3O6 [M+1]+512.0.
Step 3: BCl3 (1 M in CH2Cl2, 78 ml, 78 mmol) solution was added to a solution of compound 7 (10 g, 19.57 mmol) in dry CH2Cl2 (400 ml) at −15° C. After the addition of BCl3, the mixture turned yellow and precipitate started to form. The reaction was warmed to 0° C. After the reaction was complete (checked by TLC), the mixture was poured into ice-water (600 ml). The yellow precipitate was filtered, washed with water, and dried (Na2SO4) to give the title compound 8 as a yellow solid (8.5 g, 17.1 mmol, 87%). MS: C24H14F3N3O6 [M+1]+498.1.
Step 1: To a suspension of compound 8 (0.35 g, 0.7 mmol) in dry DMF (16 ml), compound 9 (3-aminomethyl benzothiophene) (0.11 g, 0.7 mmol), DI PEA (0.18 g, 1.4 mmol) and HATU (0.53 g, 1.4 mmol) were added at RT. After 30 ml, the reaction mixture was poured into cold water (30 ml). The precipitate was filtered, washed with water and dried under vacuum to give crude compound 10 (0.45 g, 0.7 mmol) as a yellow solid.
Step 2: The crude material of compound 10 (0.45 g, 0.7 mmol) was treated with absolute EtOH (15 ml) and 98% hydrazine (0.22 g, 7 mmol) at RT overnight. The reaction mixture was evaporated and purified on a Biotage (40 M) system, eluting with 3% NH4OH:CH3OH (1:9)/97% CH2Cl2. Compound 11 was obtained as a pure yellow solid (0.22 g, 0.43 mmol, 61% yield) which was converted to its HCl salt by treatment with 1.2 equivalent of 4 N HCl/dioxane in CH2Cl2. Compound 12 was obtained by evaporating off solvents and excess acid. MS (M+1): m/e. 513.
A series of aromatic or heteroaromatic amide analogs (compound 13) was made by methods analogous to those described for compound 12 in Example 3 or via an alternative coupling method by treatment of compound 8 (0.2 mmol) either with aromatic or heteroaromatic amine reagent (0.2 mmol), DEC (0.24 mmol), HOBT (0.24 mmol), and TEA (0.24 mmol) in DMF (2.5 ml) at RT overnight. Water (3 ml) was added to the reaction and precipitate was collected, rinsed with water, and vacuum dried at 40° C. The phthalamido protecting group of the coupled product was removed with 98% hydrazine in EtOH (as in step 2 of Example 3) and purified by silica gel chromatography [5% NH4OH—CH3OH (1:9) in 95% CH2Cl2] or by preparative Gilson Prep column (XTerra RP C18, 5 μm) chromatography, gradient eluted with 0.5% TFA in (9:1) (H2O—CH3CN) to 0.5% TFA in CH3CN:H2O (8:2). Compound 13 was obtained as free form or as a TFA salt, depending on the method of purification. The free form of compound 13 was treated with 1.2 equivalent of HCl to give compound 13 as a HCl salt. The data for compound 13 analogs are listed as follows:
Step 1: Glycine ethyl ester hydrochloride (14 g, 100 mmol) was mixed with TEA (29 ml, 200 mmol) in dry CH2Cl2 and cooled in an ice-water bath. Compound 2 (80 mmol) (see Example 1) in dry CH2Cl2 (150 ml) was transferred by cannulation into the above cooled solution. The resulting mixture was allowed to warm to RT slowly. After 2 h, reaction was complete and water (300 ml) was added to dissolve the TEA salt. The organic layer was separated, washed with 5% HCl solution, then water, dried (Na2SO4), filtered and concentrated to give a crude solid, Compound 14, which was used in the next step without further purification.
Step 2: Compound 14 (7.2 g, 20 mmol) was mixed with Lawesson's reagent (5.5 g, 13.6 mmol) in anhydrous THF (100 ml) and heated to 78° C. for 40 min. After cooling to RT, THF was removed and product was purified by silica chromatography, eluting with 100% CH2Cl2 to 5% EtOAc in CH2Cl2, to give compound 15 as a yellow product.
Step 3: Compound 15 (3.9 g, 10 mmol) was dissolved in dry CH2Cl2 (40 ml) and cooled to −78° C. Trimethyloxonium tetrafluoroborate (1.6 g, 11 mmol) was added in one portion. The resulting mixture was then stirred in an ice-water bath for 2 h. NaHCO3 solution was added to quench the reaction. The organic layer was separated, washed with H2O, dried (Na2SO4), and evaporated to give compound 16 as a crude solid which was used in the next reaction without purification.
Step 4a:
A neat liquid of cyanuric fluoride (3.4 ml, 40 mmol) was added dropwise to a cooled solution of N-[(1,1-dimethylethoxy)carbonyl]-L-alanine (compound 17) (3.90 g, 20 mmol) in pyridine (1.78 ml, 22 mmol) and dry CH2Cl2 (50 ml) at −40° C. The reaction was kept at −30° C. to −10° C. for 2 h. After 2 h, crushed ice and CH2Cl2 (100 ml) were added. After stirring for 5 min, the mixture was filtered twice, first with a coarse, then with a medium glass filter funnel. The clear solution was separated and the organic phase was washed with H2O, dried (Na2SO4), filtered and concentrated at RT to give compound 18 as a white solid (3.59 g, 18.7 mmol) with a 94% yield.
Step 5: Compound 18 (2.87 g, 15 mmol) was added to a solution of compound 16 (5.0 g, 12.5 mmol) in dry THF (60 ml). The reaction mixture was cooled to −78° C. and KHMDS (0.5 M in toluene) (52.5 ml, 26.25 mmol) was added dropwise over 40 min. During the addition of the first equivalent of base, the reaction mixture turned a deep blue color, which disappeared immediately. A deep brown color was formed when the second equivalent of base was added. The reaction solution was kept at −78° C. for 1 h then gradually warmed to RT. After completion of the reaction (checked by TLC), ice-cold 0.5 M HCl solution (70 ml) was added. The organic layer was separated and the aqueous layer was extracted with EtOAc (70 ml). The combined organic layer were washed with NaHCO3 solution and brine, dried (Na2SO4), filtered and concentrated to give a crude product which was purified by silica gel chromatograph to yield compound 19 as a solid (3.5 g, 6.88 mmol, yield 55%). Alternative method for the preparation of compound 19:
Step 4b:
A mixture of BOC-L-alanine (17b) (2.9 g, 15.4 mmol), p-nitrophenol (3.3 g, 15.4 mmol) and DCC (3.3 g, 16.2 mmol) in EtOAc (60 ml) was stirred at RT for 2 h. A white precipitate was formed; the solid was filtered off and the filtrate was evaporated. The crude material was purified on a Biotage silica column, eluting with 20% hexane in CH2Cl2 to give compound 18b (2.8 g, 9 mmol, 58.4% yield) as a yellow solid. LCMS C14H18N2O6 [M+1]+311.1.
Step 5b: By a method analogous to that described in Example 5, Step 5, using compound 18b in place of compound 18, compound 19 was prepared.
Step 6: At 0° C., LiOH solution (150 mg, 6 mmol, in 15 ml of H2O) was added to a solution of compound 19 (1.02 g, 2 mmol) in THF (37 ml). After 1 h at 0° C., the reaction was gradually warmed to RT and stirred at RT overnight. After the reaction was complete, EtOAc (50 ml) and H2O (5 ml) were added, followed by the addition of 1 N HCl to acidify the mixture. The organic phase was separated, dried (Na2SO4), filtered and concentrated to give the title compound 20 as a white solid (0.94 g, 1.95 mmol, 98% yield). MS: C22H22F3N3O6 [M+1]+482.1.
Step 1: A mixture of 4-chlorobenzaldehyde (21) (0.79 g, 5.45 mmol), 2-hydroxyethyl amine (22) (0.34 ml, 5.45 mmol) and Na2SO4 (1.44 g, 10.9 mmol) in dichloroethane (40 ml) was stirred at RT for 40 min. To this mixture, NaBH(OAc)3 (3.12 g, 14.72 mmol) and AcOH (0.82 ml, 13.67 mmol) were added. After stirring at RT overnight, the reaction was quenched with saturated NaHCO3 solution. The mixture was diluted with brine (200 ml) and extracted with CH2Cl2 (100 ml, 3×), combined and washed with brine (100 ml, 2×), dried (MgSO4), filtered and evaporated to give crude compound 23 as an oil. The oil was purified with flash grade silica gel (100 g), eluting with 5% (1:9) (NH4OH/CH3OH)/95% CH2Cl2 to yield compound 23 (0.3 g, 1.62 mmol, 30% yield).
Step 2: A mixture of compound 20 (0.241 g, 0.5 mmol), compound 23 (92.8 mg, 0.5 mmol), HATU (285 mg, 0.75 mmol) and DIPEA (0.131 ml, 0.75 mmol) in dry DMF (3.0 ml) was stirred at RT for 4 h. After the reaction was complete, water (3 ml) was added to quench the reaction and the mixture was stirred for 10 min. Solid was collected, rinsed with water, and redissolved in CH2Cl2 (10 ml), dried (Na2SO4), filtered and evaporated. Product was purified by flash grade silica gel (100 g), eluting with 4.5% (1:9) (NH4OH/CH3OH)/95% CH2Cl2 to give pure compound 24 (0.18 g, 0.28 mmol, 56% yield) as a solid.
4 N HCl-dioxane solution (0.8 ml, 3.2 mmol) and CH3OH (1 ml) were added to a solution of compound 24 (0.18 g, 0.33 mmol) in CH2Cl2 (2 ml). The mixture was stirred at RT overnight. Solvents were evaporated and product was triturated with CH2Cl2, filtered and dried under high vacuum to give title compound 25 as a HCl salt. LCMS: C26H24F3N4O4Cl. HCl [M+1]+549.1
By employing methods analogous to those described in Example 6, Step 2, the following compounds were prepared using an appropriate aromatic or heteroaromatic amine coupled with compound 20 either by HATU or DEC (Example 4). The data for compounds of formula 26 are as follows:
Using N-[(1,1-dimethylethoxy)carbonyl]-O-(1,1-dimethylethyl)-L-serine (compound 27) as starting material, [1(S)-[(1,1-dimethylethoxy)methyl]-2-fluoro-2-oxoethyl] carbamic acid, 1,1-dimethylethyl ester (compound 28) was prepared by a method analogous to that in Example 5, step 4.
0.5 M KHMDS in toluene (92.5 ml, 46.25 mmol) was added slowly via a syringe to a mixture of compound 16 (8.5 g, 22 mmol) and compound 28 (6.8 g, 25.8 mmol) in dry THF (90 ml) at −78° C. The mixture was slowly warmed to RT, then stirred at RT for 1 h. After the reaction was complete, it was quenched with 1 N HCl (80 ml)(cooled with ice-water bath), diluted with saturated NH4Cl solution (100 ml), extracted with EtOAc (200 ml×2), dried (Na2SO4), filtered and evaporated. Crude material was purified on Biotage with CH2Cl2 (4 L) and 5% EtOAc/CH2Cl2 (4 L) to give compound 29 as a light yellow solid (6.5 g, 11.8 mmol, 52%). MS C28H34F3N3O7 [M+1]+582.1.
Compound 29 (13.5 g, 23.24 mmol) was treated with THF:H2O (2:1) (200 ml) and LiOH.H2O (0.95 g, 39.6 mmol) (dissolved in 10 ml of H2O). After stirring at RT for 2 h, the suspension was not dissolved. Additional THF:H2O (2:1) (100 ml) and LiOH.H2O (0.95 g, 39.6 mmol) was added. It was stirred at RT overnight. After completion, the reaction was neutralized with 1 N HCl. The mixture was extracted with CH2Cl2 (100 ml×3), combined, washed with brine (100 ml), dried (Na2SO4), filtered and evaporated to give the title compound 30 as a yellow solid (11.8 g, 21.3 mmol, 92%). LCMS: C26H3F3N3O7 [M+1]+554.1.
By a method analogous to Example 2, using 5-fluoro-3-methyl-benzo[B]-thiophene (31) as starting material, compound 33 was obtained. It was treated with 10 equivalents of 98% hydrazine in absolute EtOH and CH2Cl2 (1:1) to give compound 34, which was purified by treatment with a slight excess of 4 N HCl/dioxane solution to give compound 35 as a HCl salt. FABMS: C9H8FNS. HCl [M+1]+182.0
By methods analogous to those described in Example 3, using compound 35 as a starting material, compound 36 was obtained.
The protecting groups on compound 36 were removed by treatment with HCl-dioxane/CH2Cl2 or CF3COOH. The title compound 37 was obtained directly as a HCl salt or as a TFA salt depending on the acid treatment. The TFA salt was neutralized with NH4OH and converted to HCl salt with 1.0 equivalent of HCl. HRMS C26H20F4N4O4S. HCl calculated [M+1]+561.1220, Found 561.1230.
By employing analogous methods to those described in Example 10, the following compounds were obtained as HCl salts using compound 30 coupled with the appropriate primary or secondary amine, followed by removal of the protecting group as described for Example 10, step 3.
By employing methods analogous to those described for Example 5, using compound 18c in place of compound 18, compound 42 was obtained, which was treated with LiOH.H2O to give the title compound 43.
By employing methods analogous to those described in Example 6, using compound 43 in place of compound 20 and 4-chlorobenzylamine in place of compound 23 in the coupling reaction, compound 44 was obtained. After removal of the t-BOC group of compound 44 with HCl, the title compound 45 was obtained as a HCl salt. MS: C25H22ClF3N4O3. HCl [M+1]+519.1.
Using a procedure similar to that described for compound 45, the following compounds were prepared:
By employing methods analogous to those described in Example 6, using compound 43 in place of compound 20 and compound 9 in place of compound 23 compound 46 was obtained. After removal of the t-BOC group of compound 46 with HCl, the title compound 47 was obtained as a HCl salt. MS C27H23F3N4O3S .HCl [M+1]+541.1.
By employing methods analogous to those described in Example 5, using compound 18d in place of compound 18, compound 48 was obtained, which was treated with LiOH.H2O to obtain the title compound 49.
By employing methods analogous to those described in Example 6, using compound 50 in place of compound 20 and 2,4-diflurobenzylamine in place compound 23, compound 51 was obtained. After removal of the t-BOC group of compound 51 with HCl, the title compound 52 was obtained as a HCl salt. MS: C26H23F5N4O3. HCl [M+1]+535.
Using similar procedures and the appropriate staring materials, the following compounds were also prepared:
By employing methods analogous to those described in Example 5, using compound 18e in place of compound 18, compound 53 was obtained, which was treated with LiOH.H2O to yield the title compound 54.
By employing methods analogous to those described in Example 10, using compound 55 in place of compound 30 and 1-amino-2-hydroxyethyl benzene in place of compound 35, compound 56 was obtained. After purification and removal of the t-BOC group of compound 56 with HCl, compound 57 was obtained as a HCl salt. MS: C26H25F3N4O5. HCl [M+1]+567.1.
Using the appropriate aromatic or heteroaromatic amine reagent coupled with compound 55 according to the procedure described for Example 10, steps 2 and 3, the desired compound 58 was obtained as a hydrochloride salt.
By employing methods analogous to those described for Example 20, replacing compound 59 with 62 and 60 with 63, the title compound 64 was obtained as an amine HCl salt. LCMS C9H11O2N. HCl [M+1]+166.0
NaBH4 (0.7 g, 18.5 mmol) at RT was added to a solution of compound 65 (0.6 g, 3.57 mmol) in MeOH (20 ml) cooled with a water bath. After 10 min, solvent was removed. The residue was treated with 5% NaHCO3 and the product was extracted with CH2Cl2, then with EtOAc. The combined organic solution was washed with brine, dried (Na2SO4), filtered and concentrated to give compound 66 as a white solid. Using a method similar to Example 27, the title compound 67 was obtained as a HCl salt. LCMS C7H11N3O2.HCl [M+1]+170.0
Solid 1,3,5-triazine (2.4 g, 30 mmol) (68) was mixed with 1-(pyrrolidino)-1-cyclohexene (69) in a pressure tube (15 ml) and heated at 93° C. (bath temperature) with stirring for 22 h. After completion of the reaction, the reaction mixture was concentrated and dissolved in CH2Cl2, washed with saturated NaHCO3 solution, dried (Na2SO4), then purified by column chromatography to give compound 70 as a solid.
The title compound 73 was prepared according to the procedure described for Example 2, and step 2 of Example 3.
A mixture containing 3-acetylthianaphthene (74) (0.5 g, 2.8 mmol), allylamine (0.42 g, 5.6 mmol), NaBH(OAc)3 (1.2 g, 5.6 mmol), and HOAc (0.15 ml) in dichloroethane (15 ml) was stirred at RT overnight. After completion, the reaction mixture was quenched with NaHCO3 and extracted with CH2Cl2. The organic solvent was dried (Na2SO4), filtered and evaporated. The crude material was purified by column chromatography to give compound 75 (0.43 g) as an oil.
N,N-dimethylbarbituric acid (0.65 g, 4.14 mmol) and tetrakis-(triphenyl-phosphine)palladium (16 mg, 0.0138 mmol) were added to a solution of compound 75 (0.3 g, 1.38 mmol) in CH2Cl2 (30 ml). The mixture was stirred at 40° C. for 2 h, then at RT overnight. After completion of the reaction, the mixture was diluted with CH2Cl2 and washed with saturated Na2CO3 solution. The organic layer was separated and the aqueous layer was re-extracted with CH2Cl2. The organic fractions were combined and concentrated. The crude material was purified by silica gel chromatography to give the title compound 76 as an oil.
Compound 94 was prepared according to the literature (Tetrahedron Letters 41, 8661-8664, (2000)). Compound 94 (3.0 g, 22.5 mmol) was mixed with NaI (3.37 g, 22.5 mmol) and NaN3 (1.9 g, 29 mmol) in CH2Cl2/acetone (1:1, 250 ml) and refluxed for 36 h. After completion of the reaction, the reaction mixture was filtered and the filtrate concentrated to dryness. Crude compound 95 was purified on Biotage system, eluting with 2% MeOH in CH2Cl2, to obtain pure compound 95 as a white solid. Compound 95 (2.46 g, 17.6 mmol) was dissolved in MeOH (100 ml) and formic acid (0.81 ml, 17.6 mmol), and 10% Pd/C (490 mg) was added. The mixture was stirred at RT under a H2 balloon overnight. The solids were filtered off and the filtrate was evaporated to give the title compound, 96, as a formic acid salt. MS: C3H6N4O [M+1]+115.
The following intermediates were synthesized by using a similar procedure:
The following intermediates were synthesized by using a similar procedure:
To a solution of compound 102D (0.73 g, 2.62 mmol) suspended in CH2Cl2 (18 ml) was added TFA (3 ml). The reaction mixture was stirred at RT for 3 h. The solvent was evaporated, and the TFA salt of the product was dissolved in MeOH (20 ml). Diethylaminomethylpolystrene resin (4 g, Fluka) was added and stirred at RT for 20 min. The resin was removed by filtration and washed with MeOH. The filtrate was concentrated to give 0.47 g (2.62 mmol, 100%) of the product 103B as a yellow solid. MS (M+1-OH): m/e 162.
The following intermediates were synthesized by using a similar procedure:
The following intermediates were synthesized by using a similar procedure:
The following intermediate was synthesized by using a similar procedure:
The following intermediate was synthesized by using a similar procedure:
The following intermediate was synthesized by using a similar procedure:
The following intermediates were synthesized by using a similar procedure:
The following intermediates were synthesized by using a similar procedure:
The following intermediate was synthesized by using a similar procedure:
The following intermediates were synthesized by using a similar procedure:
The following intermediates were synthesized by using a similar procedure:
2,4,6-Trifluorobenzylamine 128 was prepared according to the literature procedure of A. Marfat et al, WO 9845268.
The following intermediates were synthesized by using a similar procedure:
Anhydrous CeCl3 (1.85 g, 7.5 mmol) was suspended in THF (25 ml) under N2 and stirred overnight at RT. EtMgBr (2.5 ml of 3.0 M in THF, 7.5 mmol) was added dropwise, and the reaction mixture was stirred at RT for 1 h. A solution of ketone 162 (463 mg, 2.5 mmol) dissolved in THF (5 ml) was added dropwise to the suspension, and the resulting mixture was stirred at RT for 2 h. The reaction mixture was treated with EtOAc (5 ml) for 30 min at 20° C. and 2 M HCl, respectively, followed by extraction with EtOAc (2×100 ml). The combined organic extract was washed with brine, dried (MgSO4), filtered, and concentrated to give the crude intermediate. This intermediate was dissolved in minimal EtOAc and HCl (10 ml of 2 M in Et2O) was added. The reaction mixture was stirred at RT overnight to give the product 163 as a precipitate. The precipitate was filtered, washed with EtOAc, and dried in vacuo to give the product 163 as brown solid (276 mg, 73%). (M+1): m/e 116.
MS (M+1): m/e 233.
Step 3: Using the procedure of step 1 from Example 32, the isomers 236A (from 235A) and 236B (from 235B) were synthesized. MS (M+1): m/e 485.
Step 4 and Step 5: Using the procedure of step 2 from Example 32 and then step 3 from Example 31, the compounds 237A (from 236A) and 237B (from 236B) were synthesized. MS (M+1): m/e 472.
Step 1: Solid t-BuOK (2.20 g, 20 mmol) was dissolved in dry THF (50 ml) and cooled to −78° C. Compound 239 (5.34 g, 20 mmol) dissolved in dry THF (20 ml) was added while the reaction mixture was maintained at −78° C. After stirring at −78° C. for 30 min, the solution was cannulated into a vigorously stirred solution of compound 238 (20 mmol) dissolved in dry THF (50 ml) and also cooled to −78° C. The reaction mixture was stirred at −78° C. for 30 min, then 3 N aqueous HCl solution (50 ml) was added, and the reaction mixture was stirred at RT for 1 h. The resulting mixture was concentrated, and the aqueous solution was washed with Et2O (2×75 ml). The aqueous solution was concentrated by co-evaporation with toluene at temperature <40° C. The residue was dried under vacuum overnight, then suspended in MeOH (500 ml) and stirred at RT. The insoluble salt was removed by filtration. The filtrate was concentrated, and dried in a vacuum oven at 50° C. overnight to give the product 240 (6.6 g, 76%, HCl salt) as a solid. MS (M+1): m/e 397.
Step 2: To a solution of compound 241 (10 mmol) dissolved in dry THF (60 ml) and cooled to −78° C. was added compound 240 (4.3 g, 10 mmol) dissolved in dry DMF (30 ml) and then Et3N (2.7 ml, 20 mmol). The reaction mixture was stirred at RT for 3 days. The resulting mixture was concentrated and the residue was dissolved in EtOAc/Et2O. The organic solution was washed with 1 N HCl, 10% NaHCO3, and brine, dried (Na2SO4), filtered, and concentrated. Purification by silica gel chromatography gave 242 (4.2 g, 65%) as pale solid. MS (M+1): m/e 650.
Step 3: Compound 242 (2.0 g, 3 mmol) was dissolved in dry p-xylene (60 ml) and 7 N NH3/MeOH (2 ml) and TFA (2.2 ml) was added. The reaction mixture was heated at 150° C. for 2 h and then 0.5 N NH3/dioxane (15 ml) and AcOH (2 ml) were added. The resulting mixture was heated at 160° C. with azeotropic removal of water overnight, cooled to RT, and concentrated. Purification by silica gel chromatography (20% EtOAc in CH2Cl2) gave the product 243 (0.51 g, 27%) as a light-yellow solid. MS (M+1): m/e 631.
Step 4: Compound 243 (0.46 g, 0.73 mmol) was dissolved in AcOH (20 ml) and concentrated HCl (10 ml) and was heated to reflux for 24 h. The resulting mixture was concentrated and water (50 ml) was added. The precipitate was collected by filtration, washed with water, and dried in a vacuum oven at 50° C. overnight, to give the product 244 (0.41 g, 93%). MS (M+1): m/e 603.
Step 5: To a solution of compound 244 (0.12 g, 0.2 mmol) dissolved in dry DMF (0.5 ml) and CH2Cl2 (3 ml) was added 2,4-difluorobenzylamine (0.05 ml, 0.4 mmol), DIPEA (0.07 ml, 0.4 mmol), and HATU (0.114 g, 0.3 mmol). The resulting mixture was stirred at RT overnight and then concentrated. The residue was dissolved in DMF (2 ml) and purified by Gilson reverse phase prep HPLC to give the product 245 (0.081 g, 56%). MS (M+1): m/e 728.
Step 6: Compound 245 (0.080 g, 0.11 mmol) was dissolved in Et2NH (2 ml) and CH3CN (2 ml) and stirred at RT for 30 min. The resulting mixture was concentrated, and the residue was purified by Gilson reverse phase prep HPLC. The product was treated with HCl in ether, then dried in a vacuum oven at 50° C. overnight to give the product 246 (0.052 g, 94%) as a di-HCl salt. MS (M+1): m/e 506.
Step 1: To a solution of compound 247 (38 g, 0.19 mol) dissolved in CH2Cl2 (450 ml) and cooled to 0° C. was added Et3N (35 ml, 0.25 mol) and t-Boc anhydride (54 g, 0.25 mol). The reaction mixture was stirred at RT overnight. The resulting mixture was diluted with CH2Cl2, washed with 1 N HCl solution, dried (Na2SO4), filtered, and concentrated. Purification by silica gel chromatography gave the product 248 (47 g, 96%). MS (M+1): m/e 260.
Step 2: To a solution of compound 248 (1.55 g, 6 mmol) dissolved in dry THF (60 ml) and cooled to 0° C. was added triphenylphosphine (2.0 g, 7.8 mmol), diethyl azodicarboxylate (1.3 ml, 7.8 mmol) dropwise, and then diphenylphosphoryl azide (1.7 ml, 7.8 mmol). The reaction mixture was stirred at RT overnight, then diluted with ether. The organic solution was washed with saturated NaHCO3 and brine, dried (Na2SO4), filtered, and concentrated. Purification by silica gel chromatography (eluant: 15-20% EtOAc in hexane) gave compound 249 (1.7 g, 100%). MS (M+1): m/e 285.
Step 3: To a solution of compound 249 (0.5 g, 1.76 mmol) dissolved in THF (40 ml) was added 10% Pd/C catalyst (0.25 g). The reaction mixture was stirred under H2 (1 atm) at RT overnight. The resulting mixture was filtered, and the filtrate was concentrated to give the product 250 (0.45 g, 100%). MS (M+1): m/e 259.
Step 4 and 5: To a solution of compound 250 (0.13 g, 0.5 mmol) dissolved in CH2Cl2 (1 ml) was added DIPEA (0.2 ml) and cyclopropanecarbonyl chloride (0.053 ml, 0.5 mmol). The reaction mixture was stirred at RT for 2 h. The resulting mixture was diluted with EtOAc. The organic solution was washed with 1 N HCl, saturated NaHCO3, and brine, dried, filtered, and concentrated. Purification by silica gel chromatography gave the product 251. Compound 251 was treated with 4 N HCl in dioxane at RT for 4 h. The resulting mixture was concentrated, and the residue was dried under vacuum for 2 days to give the product 252 as the HCl salt (0.1 g, 76%). MS (M+1): m/e 227.
Step 6: To a solution of compound 248 (3.1 g, 12 mmol) dissolved in dry THF (100 ml) and cooled to 0° C. was added triphenylphosphine (4.0 g, 15 mmol), DEAD (2.5 ml, 15 mmol) dropwise, and LiBr (5 g, 57 mmol). Within 2 min, all the LiBr dissolved. The resulting clear yellow solution was stirred at RT overnight. The reaction mixture was diluted with EtOAc, washed with water, dried (Na2SO4), filtered, and concentrated. Purification by silica gel chromatography gave the product 253 (2.15 g, 56%). MS (M+1): m/e 323.
Step 7: To a solution of compound 253 (2.1 g, 6.5 mmol) dissolved in DMSO (15 ml) was added NaN3 (0.46 g, 7 mmol). The resulting mixture was stirred at RT for 2 days. Water was added to the mixture and product was extracted with ether (3×40 ml). The combined organic layer was washed with brine, dried (Na2SO4), filtered, and concentrated to give the product 254.
Step 8: Using the procedure of step 3, compound 255 was synthesized. MS (M+1): m/e 259.
Step 9: To a solution of compound 255 (0.26 g, 1 mmol) dissolved in DMF (2 ml) was added Et3N (0.28 ml, 2 mmol) and 2-bromopyrimidine (0.16 g, 1 mmol). The reaction mixture was heated at 100° C. overnight then cooled to RT. The resulting mixture was diluted with DMSO (3 ml) and purification by reverse phase Gilson prep HPLC gave the product 256 (0.18 g, 54%). MS (M+1): m/e 337.
Step 10: Using the procedure of step 5, compound 257 was synthesized. MS (M+1): m/e 237.
Step 1: Compound 258 (4.14 g, 13.6 mmol), CuI (288 mg, 0.37 mmol), NaI (4.32 g, 28.8 mmol), and sym-dimethylethylenediamine (0.38 ml, 0.72 mmol) were suspended in toluene (12 ml). The reaction mixture was heated in a sealed tube at 125° C. for 48 h. The resulting mixture was cooled to RT and filtered through celite. The filtrate was concentrated, and the residue was purified by silica gel chromatography (eluant: 1:10 EtOAc:hexane) to give the product 259 (4.06 g, 85%) as a beige liquid. MS (M+1): m/e 354.
Step 2: Compound 259 (3.55 g, 10.0 mmol), pyrazole 260 (2.31 g, 15 mmol), trans-1,2-di(methylamine)cyclohexane (450 mg, 3.17 mmol), CuI (190 mg, 1.0 mmol), and K2CO3 (4.14 g, 30 mmol) were suspended in toluene (40 ml). The reaction mixture was heated in a sealed tube at 125° C. for 10 days. The resulting mixture was cooled to RT and filtered through celite. The filtrate was concentrated and the residue was purified by silica gel chromatography (eluant: 1:1 EtOAc:hexane) to give the starting compound 259 (2.1 g, 46%) and the product 261 (1.29 g, 45%) as a white solid. MS (M+1): m/e 380.
Steps 3, 4, and 5: Using procedures similar to that of step 1 from Example 2, step 3 from Example 55, and step 4 from Example 55, intermediate 262 was synthesized.
MS (M+1): m/e 495.
Step 6: Using a procedure similar to that of step 1 from Example 32, compound 263 was synthesized. MS (M+1): m/e 467.
Steps 7 and 8: Using procedures similar to that of step 2 from Example 32 and step 3 from Example 31, the following compounds were synthesized.
Using procedures from Examples 5 and 6, compound 266 was synthesized. MS (M+1): m/e 439.
The pharmacological activity of the compounds of the invention was measured by the following assays.
PDE4 Screening Assay
1. Human PDE4 Enzyme
The neutrophils were isolated from human blood using a standard procedure, then homogenized with a glass-glass homogenizer in a buffer containing 20 mM Tris/HCl (pH 8.0), protease inhibitor cocktail tablet (Cat. No. 1836145/Boehringer Mannheim), 2 mM EDTA, 1% Triton X-100 and 0.5% deoxycholate. After stirring for 2 h at 4° C., the samples were centrifuged at 100,000 g for 1 h. The supernatants were collected, filtered and applied to Mono Q column chromatography. The fractions containing the activity of hydrolyzing cAMP were determined and pooled as the enzymatic source of the PDE4 screening assay.
2. PDE4 Assay and Compound Screening
The PDE4 assays were performed using Phosphodiesterase [3H]cAMP SPA enzyme assay kits and its procedures (Cat. No. TRKQ 7090, Amersham). The assay procedures are described briefly as follows. The diluted PDE4 enzyme, 10× assay buffer and water were mixed at a ratio of 1:1:6 (10 μl/10 μl/60 μl). 80 μl aliquots of this mixture were added into the test wells of a 96-well Microlite plate (Cat. No. 7416, ThermoLabsystems). Enzyme dilution buffer, instead of the diluted enzyme, and water were added into the wells of negative control (background). 10 μl test compounds in 10% DMSO, standard inhibitor in 10% DMSO or 10% DMSO (for positive and negative controls) were added into the corresponding wells, respectively. After a 10 min incubation at RT, the reactions were initiated by addition of 10 μl pre-diluted [3H]cAMP into each well, then incubated at 30° C. for 30 min. The reactions were stopped by addition of 50 μl SPA beads into the test wells, then counted in a β-counter over 30 min ˜24 hr.
10× Assay Buffer: 500 mM Tris/HCl pH 7.5, 83 mM MgCl2, 17 mM EGTA
[3H]cAMP: [3H] cAMP (40-60 Ci/mmol) is diluted at a 1:200 ratio with water. The final concentration is 0.005 μCi/μl
Yttrium SPA Beads: 500 mg of beads was reconstituted with 28 ml of water, stored at 4° C.
PDE10 and 11 Screening Assay
PDE10 (human recombinant PDE10A2, expressed in Sf9 insect cells by the baculovirus expression technique) was assayed using [3H]cGMP PDE SPA Assay kit (Amersham) at a final concentration of cGMP of 0.7 μM. PDE11 (human recombinant PDE11A3, expressed in Sf9 insect cells by the baculovirus expression technique) was assayed using [3H]cAMP PDE SPA Assay kit (Amersham) at a final concentration of cAMP of 0.0125 μM. Compounds were evaluated at 0.1-10,000 nM in 2% DMSO and 0.1% BSA from a stock solution of 4 mM in 100% DMSO. All assays were performed in duplicate, and each set of experiments was performed at least twice. Analysis of dose-response data and calculation of IC50 values were performed using GraphPad Prism.
PBMC (Peripheral Blood Mononuclear Cell) Preparation and TNF Inhibition Assay
This protocol was modified from Prabhaker et al. (Int. J. Immunopharmac, Vol 16, No 10 pp 805-816, 1994. Smithkline Beecham Pharmaceuticals).
C57BI/6 mice were injected with 25 ug of LPS (LPS O55-B5, Sigma: L2880) by the intraperitoneal route. One hour prior to injection of the LPS, mice were treated orally with the PDE4 compounds at the selected doses. Ninety min after the LPS challenge, the mice were euthanized, and blood was collected through a heparinized syringe tip into Capijet T-MGA tubes. The blood was centrifuged for 10 min in a microcentrifuge at maximum speed (−13,000 rpm), and the serum was collected and analyzed for TNFα protein using an R&D ELISA kit.
Lipopolysaccharide (LPS) in vivo Assay
Male Sprague/Dawley rats (200-250 g) were purchased from Charles River Laboratories. Prior to use, the animals were permitted unrestricted access to food and water. Test compounds were delivered by gavage 5 hours prior to LPS-challenge. Compounds were suspended in a 0.4% methylcellulose vehicle with the same vehicle being given to control animals.
LPS-treatment: Animals were anethesized by inhalation of isoflurane, supplemented with oxygen (flow rate 1.0 ml/min). Once anesthetized, animals were placed supine and the trachea visualized using a small laryngoscope. Animals then received either 0.1 ml of saline or 0.1 ml of a 100 μg/ml lipopolysaccharide solution (LPS; E. coli) in saline by use of a Penn-Century Microspray needle (Penn-Century, Philadelphia, Pa.). Animals were allowed to recover on a heat pad, returned to housing and permitted access to food and water ad libitium. Sixteen hours after LPS-challenge, animals were anesthetized with an intra-peritoneal injection of the combination of ketamine/xylazine (10:1, 200 mg/kg ketamine, 20 mg/kg xylazine). After reaching anesthesia, animals were surgically prepared for bronchial lavage by inserting a tracheal cannula. Animals were lavaged with 2×2 ml of phosphate buffered saline, pH 7.2 (PBS). Routine recovery of BAL fluids did not significantly differ between animals with >80% of instilled volume recovered. Afterwards, animals were euthanized by surgically opening the thoracic cavity and cutting the diaphragm to assure lung collapse. Bronchial lavage (BAL) fluid was analyzed for cellular contents as described below.
BAL samples: Bronchial lavage (BAL) fluid was spun at 350×g for 10 min at 4° C. One ml of supernatant was removed and stored at −20° C. until analyzed for cytokine levels. Remaining fluid was aspirated and the cell pellet lysed for residual erythrocytes and resuspended in PBS, pH 7.2 containing 10 ug/ml of DNase I. Afterwards, the cell suspension was centrifuged at 350×g for 10 mins at 4° C., the supernatant aspirated and the cell pellet resuspended in 1 ml of PBS with 10 ug/ml DNase 1 and 5% heat inactivated fetal bovine serum. Cytospin slide preparations were made and stained with Hema3™ staining system (Fisher Scientific, Springfield N.J.). Differential cell counts were performed using standard histological parameters and at least 200 cells were enumerated. Total cell counts were performed using a Neubauer chamber.
Assay Procedure for Testing of Dermatitis in Dogs:
Five dogs are selected for each treatment group. Administration of experimental medications begins and continues through the end of the animal phase of the experiment. After three days, all dogs are sedated using medetomadine intravenously. An approximately 5 cm by 13 cm area is shaved on the lateral thorax of each dog. 1 cc of lidocaine is injected subcutaneously, and then two 8 mm punch biopsies are taken to act as Time 0 controls. Biopsy sites are closed with simple interrupted sutures of 3-0 Nylon suture.
Ten intradermal injections are given (five rows of two injections)—two injections are of phosphate buffered saline (PBS), and the remaining eight injections are of rabbit IgG antibody to dog IgE. Each injection is 0.05 ml. The total dose of anti-IgE per injection is 7 μg, as previously determined to be optimal. After injection, sites are observed and sampled. After injection and between all future samples, all dogs wear a protective garment (Quick Cover incision cover, Four Flags over Aspen) to prevent disturbance of the injection and/or biopsy sites.
The test compounds are compounds of formula I; the negative control is phosphate buffered saline (PBS); the positive control is commercially available prednisone tablets. Tablets are given orally by placement in the back of the mouth. Liquids are given by syringe to place the test article toward the back of the mouth. The dog's mouth may be held closed to ensure that all of the test article is swallowed. Plasma samples are analyzed for the concentration of test compound from the dogs treated with the active compounds. Samples from the negative control and prednisone treated dogs need not be analyzed.
Anti-IgE Site Observations: Sites of anti-IgE injection are examined and evaluated for erythema and wheal formation. At the 20 min observation time, the two PBS sites and the two 6 hr. biopsy sites are measured. At the other post-injection times, the two PBS sites and the corresponding biopsy sites are measured. If the size of the reaction is not consistent across sites in the same dog, then all sites that have not been previously biopsied will be measured. Wheals will be measured by calipers in two orthogonal dimensions as well as measured for thickness.
Collection of Skin Samples: Two 8 mm punch biopsies are taken of the sites injected with anti-IgE. One biopsy is placed in RNA isolation buffer and the other biopsy is bisected. One half goes into a standard 10% formalin solution for routine histopathological analysis and the other is deposited in Optimal Cutting Temperature Medium and quick frozen in liquid nitrogen, then maintained at −70° C. for immunohistochemical staining with Luna's stain for eosinophils, and Alcian Blue with Nuclear Fast Red counterstain for mast cells. Using manual or computerized morphometric analysis, the extent of infiltration by the following specific leukocytes is quantitated: CD 1a+c, IgE, CD3, 4+8, TCR alpha/beta and gamma/delta, TNF alpha, and TSLP. Cytokine analysis is to determine the presence of the following: TNF alpha, IL4, IL13, IL2, IFN gamma, and Thymic stromal lymphopoietin.
Allergic Brown Norway (BN) Rat Model:
Inbred male BN rats weighing 150 to 200 g were obtained from Charles River Laboratory (Wilmington, Mass.). Prior to use, the animals were allowed food and water ad libitum. The test compounds were administered 5 h prior to antigen challenge either by oral or inhalational route, as detailed in the “delivery of test compounds” section.
Sensitization and Antigen Bronchoprovocation
The animals were divided into two main groups viz. an alum group and an antigen group. In the antigen group, animals were sensitized by an intra-peritoneal (i.p.) injection of 1 ml alum-precipitated antigen containing 20 μg of ovalbumin (OVA, grade III; Sigma chemical Co., St Louis, Mo.) and 8 mg of Al(OH)3 suspended in 0.9% saline vehicle. A booster injection of this alum-OVA mixture was given again 7 days later. Animals belonging to the alum group received injections containing alum only. Seven days after the second injection, animals were exposed to aerosolized antigen bronchoprovocation which was performed by placing the rats in an enclosed plexiglass chamber (21 liters) and exposing the rats to aerosolized OVA (1%) for 30 min. The aerosolized OVA was produced by an ultrasonic nebulizer (DeVilbiss, Somerset, Pa., USA; Model Ultra-Neb 99) at a flow rate of approximately 8 liters/min. Twenty four hours after aerosolized OVA challenge, the animals were euthanized with an overdose of pentobarbital sodium. The trachea was exteriorized and intubated, and the lungs were lavaged with two aliquots of 3 ml of physiological saline. The bronchoalveolar lavage fluid (BALF) thus collected was subjected to cell enumeration. Ten microliter of the BALF was utilized to manually enumerate the total white cells using a hemocytometer. One hundred microliter of BALF was used to prepare cytocentrifuge which was stained with Hema3™ staining system (Fisher Scientific, Springfield, N.J.) to identify and enumerate differential white blood cells such as eosinophils, neutrophils, mononuclear cells and epithelial cells. A total of 200 cells were enumerated from each cytocentrifuge. The ability of the compound to inhibit recruitment of inflammatory cells into the airways is reported.
Delivery of Test Compounds:
Oral administration: the compounds were dissolved in 0.4% methylcellulose and delivered to animals orally @3 ml/kg. An equivalent volume of 0.4% methylcellulose was given to both negative (alum group) and positive (antigen) control groups.
Intra-tracheal administration: the appropriate dose of the compound was mixed with lactose powder to achieve a final amount of 3 mg, which was delivered intra-tracheally to anesthetized animals. Animals were held in an upright position for 3-4 min and were allowed to recover from anesthesia before returning to their cages.
Using the procedures described above in the PDE 4, PDE10 and PDE11 screening assays, compounds of formula I were found to have IC50 values for PDE4 in a range of 0.01 to 500 nM, with preferred compounds having a range of 0.01 to 100 nM, more preferably 0.01 to 10 nM, and most preferably 0.01 to 3 nM. Compounds of formula I are preferably selective PDE4 inhibitors compared to PDE10 and PDE11: preferably the IC50 values for PDE10 and PDE 11 are 100 to 300 times the values for PDE4.
Representative compounds of formula I have the following IC50 values for PDE4:
For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 70 percent active ingredient. Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar, lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration.
For preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.
Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection.
Liquid form preparations may also include solutions for intranasal administration.
Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas.
Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.
The compounds of the invention may also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
Preferably the compound is administered orally or via inhalation.
Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
The quantity of active compound of formula I in a unit dose of preparation may be varied or adjusted from about 0.1 mg to 1000 mg, more preferably from about 1 mg to 300 mg, according to the particular application.
The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.
The amount and frequency of administration of the compounds of the invention and the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated. A typical recommended dosage regimen for compounds of formula I is oral administration of from 10 mg to 2000 mg/day preferably 10 to 1000 mg/day, in two to four divided doses to provide relief from allergic and inflammatory diseases or the other disease or conditions listed above.
The doses and dosage regimen of the additional agents administered in the combinations of the invention will be determined by the attending clinician in view of the approved doses and dosage regimen in the literature, e.g., the package insert, taking into consideration the age, sex and condition of the patient and the severity of the disease.
While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.
This application claims the benefit of U.S. Provisional Application 60/572,266, filed May 18, 2004.
| Number | Name | Date | Kind |
|---|---|---|---|
| 5804588 | Dyke et al. | Sep 1998 | A |
| 5834485 | Dyke et al. | Nov 1998 | A |
| 6069151 | Dyke et al. | May 2000 | A |
| 6313116 | Dyke et al. | Nov 2001 | B1 |
| 6787552 | Sakuma et al. | Sep 2004 | B2 |
| 20040152744 | Sakuma et al. | Aug 2004 | A1 |
| 20080027101 | Ting et al. | Jan 2008 | A1 |
| Number | Date | Country |
|---|---|---|
| 2489902 | Dec 2003 | CA |
| WO 9820007 | May 1998 | WO |
| WO 0058303 | Oct 2000 | WO |
| WO 0146172 | Jun 2001 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20060106062 A1 | May 2006 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60572266 | May 2004 | US |
